Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7101866 | GLAXOSMITHKLINE | Anti-inflammatory androstane derivative |
Aug, 2021
(2 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5873360 | GLAXOSMITHKLINE | Inhalation device |
Feb, 2016
(8 years ago) | |
US7629335 | GLAXOSMITHKLINE | Anti-inflammatory androstane derivative |
Aug, 2021
(2 years ago) | |
US9333310 | GLAXOSMITHKLINE | Medicament dispenser |
Oct, 2027
(3 years from now) | |
US8113199 | GLAXOSMITHKLINE | Counter for use with a medicament dispenser |
Oct, 2027
(3 years from now) | |
US8161968 | GLAXOSMITHKLINE | Medicament dispenser |
Feb, 2028
(3 years from now) | |
US9333310 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Apr, 2028
(3 years from now) | |
US8113199 (Pediatric) | GLAXOSMITHKLINE | Counter for use with a medicament dispenser |
Apr, 2028
(3 years from now) | |
US8161968 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Aug, 2028
(4 years from now) | |
US8201556 | GLAXOSMITHKLINE | Medicament dispenser |
Feb, 2029
(4 years from now) | |
US8534281 | GLAXOSMITHKLINE | Manifold for use in medicament dispenser |
Mar, 2030
(5 years from now) | |
US8534281 (Pediatric) | GLAXOSMITHKLINE | Manifold for use in medicament dispenser |
Sep, 2030
(6 years from now) | |
US8746242 | GLAXOSMITHKLINE | Medicament dispenser |
Oct, 2030
(6 years from now) | |
US8746242 (Pediatric) | GLAXOSMITHKLINE | Medicament dispenser |
Apr, 2031
(6 years from now) |
Arnuity Ellipta is owned by Glaxosmithkline.
Arnuity Ellipta contains Fluticasone Furoate.
Arnuity Ellipta has a total of 14 drug patents out of which 3 drug patents have expired.
Expired drug patents of Arnuity Ellipta are:
Arnuity Ellipta was authorised for market use on 17 May, 2018.
Arnuity Ellipta is available in powder;inhalation dosage forms.
Arnuity Ellipta can be used as indicated for the once-daily maintenance treatment of asthma as prophylactic therapy in patients aged 12 years of age and older.
The generics of Arnuity Ellipta are possible to be released after 11 April, 2031.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-290) | Mar 01, 2026 |
New Strength(NS) | May 17, 2021 |
New Patient Population(NPP) | May 17, 2021 |
New Product(NP) | Aug 20, 2017 |
Drugs and Companies using FLUTICASONE FUROATE ingredient
Market Authorisation Date: 17 May, 2018
Treatment: Indicated for the once-daily maintenance treatment of asthma as prophylactic therapy in patients aged 12 years of age and older
Dosage: POWDER;INHALATION